Sotatercept

Introduction Overview

Generic Name

sotatercept

Brand Name

Winrevair

Dosage Form

injection for subcutaneous use

Drug Class

Agents for pulmonary hypertension

Pharmacokinetics

Absorption:
Winrevair is administered via subcutaneous injection, enabling slow and sustained absorption of sotatercept into systemic circulation. The absorption phase is characterized by gradual entry into the bloodstream, facilitating steady therapeutic drug levels. The onset of action is influenced by the subcutaneous tissue vascularity and the formulation's physicochemical characteristics. Clinical studies demonstrate that sotatercept has predictable bioavailability when given subcutaneously, with minimal variability. This route of administration is preferred to avoid first-pass metabolism and maintain adequate plasma concentrations for efficacy.

Distribution:
Once absorbed, sotatercept distributes mainly within the vascular and interstitial compartments. As a recombinant fusion protein targeting activin ligands, it circulates predominantly in plasma with limited penetration into intracellular spaces, consistent with its large molecular size. Sotatercept's distribution volume approximates plasma volume, indicating minimal extensive tissue binding or accumulation. The high affinity binding to activin A and related ligands may influence distribution kinetics by transient ligand complexing. Distribution is further influenced by binding to target molecules in pulmonary vascular tissues, where it exerts pharmacodynamic effects.

Metabolism:
Sotatercept, being a protein-based therapeutic, undergoes proteolytic degradation primarily via the reticuloendothelial system and cellular catabolic pathways. The fusion protein is metabolized into smaller peptides and amino acids by proteases throughout the body, including liver and macrophage-mediated metabolic processes. Unlike small molecule drugs, it is not metabolized by hepatic cytochrome P450 enzymes, minimizing drug-drug interaction risks related to metabolism. This proteolytic metabolism is typical of biologics and results in gradual systemic clearance.

Elimination:
The elimination of sotatercept occurs mainly through proteolytic catabolism rather than renal excretion. Its half-life allows dosing approximately every three weeks, reflecting sustained plasma levels and slow systemic clearance. Elimination kinetics are influenced by molecular size, receptor-mediated clearance, and degradation pathways. Clearance rates can be affected by patient-specific factors such as body weight and immune status. Sotatercept is not significantly eliminated unchanged in urine or feces. Monitoring of drug effect and pharmacokinetics supports dosing interval optimization for maximal therapeutic benefit with minimized toxicity.

Dosage Forms

Available Dosage Forms:
Winrevair is supplied as an injection for subcutaneous use, provided in single-dose vials. The available strengths are:
- Single-Dose Vial: 45 mg
- Single-Dose Vial: 60 mg

Dosages for Adults and Adolescents:
The typical dosing regimen for Winrevair involves administration of the appropriate dose based on body weight and clinical response, given every three weeks as a subcutaneous injection. The dose is individualized with regular monitoring of hemoglobin and platelet levels to avoid adverse effects. The subcutaneous injections are administered into the abdomen (at least 2 inches away from the belly button) or the upper thigh. The dose is adjusted or treatment delayed based on blood test monitoring before or during therapy.

Specific Patient Populations:
Winrevair is approved for use in adult patients with pulmonary arterial hypertension (PAH, WHO Group 1). Safety and efficacy in pediatric patients under 18 years have not been established. Special caution is advised in patients with risk factors for thrombosis, bleeding disorders, or fertility concerns. Pregnant and breastfeeding women are contraindicated due to risk of fetal harm and unknown breast milk excretion. Dose adjustments may be considered in patients with unstable hematological profiles, and treatment requires careful hematological monitoring.

Mechanism Of Action

Winrevair (sotatercept) operates as an activin signaling inhibitor by functioning as a fusion protein that binds with high affinity to activin A and other transforming growth factor-beta (TGF-β) superfamily ligands. These ligands are cytokines involved in diverse cellular processes including inflammation, fibrosis, vascular remodeling, and wound healing. By sequestering activin A and related ligands, Winrevair modulates signaling pathways that contribute to pathological vascular proliferation and remodeling seen in pulmonary arterial hypertension (PAH).

At the molecular level, sotatercept acts as a ligand trap, preventing activin A and other pro-fibrotic TGF-β family members from engaging their native receptors on pulmonary vascular cells. This blockade interrupts downstream SMAD2/3 and SMAD1/5/8 signaling cascades, ultimately reducing the aberrant proliferation and migration of immature vascular smooth muscle cells that contribute to vessel narrowing and increased pulmonary vascular resistance.

Biochemically, this results in a rebalancing of the disrupted signaling milieu characteristic of PAH, counteracting the excessive vascular remodeling and inflammation. Clinically, this mechanism slows or reverses the progressive structural changes in pulmonary arteries, improving pulmonary hemodynamics, reducing symptom burden, and enhancing exercise capacity and quality of life.

Comparative studies show that unlike vasodilators such as phosphodiesterase type 5 inhibitors or endothelin receptor antagonists, Winrevair targets the underlying cellular proliferation and fibrosis pathways rather than just vasoconstriction. This novel approach complements existing therapies and represents a disease-modifying strategy with potential to alter the natural history of PAH. Phase 3 clinical trials have demonstrated improved functional capacity and delayed disease progression, validating this mechanistic rationale.

Pharmacological Actions

Inhibition of activin A and related TGF-β superfamily cytokines
Modulation of SMAD signaling pathways leading to reduced vascular smooth muscle proliferation
Reduction of pathological fibrosis and inflammation in pulmonary vasculature
Normalization of pulmonary vascular remodeling processes
Improvement of pulmonary arterial pressure and vascular resistance
Enhancement of exercise capacity and physical activity tolerance in PAH patients
Regulation of red blood cell production, with effects on hemoglobin levels
Potential modulation of cardiac cellular signaling by altering TGF-β ligand availability
Reduction of atherosclerotic plaque progression associated with activin signaling
Disease modification in pulmonary arterial hypertension via targeting underlying pathology
Complementary effects in PAH when combined with vasodilators like endothelin receptor antagonists
Prolonged pharmacodynamics with dosing interval of approximately three weeks

Therapeutic Or Clinical Uses

Treatment of pulmonary arterial hypertension (PAH) WHO Group 1 in adult patients
Improvement of exercise capacity and physical functioning in PAH
Reduction in symptoms associated with PAH, such as dyspnea and fatigue
Slowing or reversal of pulmonary vascular remodeling and fibrosis
Reduction of pulmonary vascular resistance and mean pulmonary arterial pressure
Adjunctive therapy to standard PAH treatments to enhance clinical outcomes
Potential reduction in hospitalization or clinical worsening events related to PAH
Management of progressive pulmonary hypertension where conventional therapies are insufficient
Treatment aimed at modifying disease progression rather than symptom management alone
Potential fertility considerations related to PAH therapy in reproductive-aged patients
Bridge therapy consideration in patients awaiting lung transplantation due to PAH severity
Use in adult patients able to self-administer subcutaneous injections
Off-label investigation in other TGF-β related fibrotic or inflammatory conditions (under research)
Use in patients without contraindications to biologic therapy involving activin pathways
Treatment initiation requiring hematologic monitoring and individualized dosing

Side Or Adverse Effects

Elevated hemoglobin levels (erythrocytosis) increasing risk of thrombosis and stroke
Severe thrombocytopenia leading to increased bleeding risk
Serious bleeding events including gastrointestinal bleeding, hematuria, and abnormal bruising
Headache occurring in approximately 10% or more of patients
Epistaxis (nosebleeds) as a common adverse effect
Skin rash and redness at injection site or generalized
Dizziness and lightheadedness potentially related to vascular effects
Diarrhea reported in a subset of treated patients
Visible spider veins (telangiectasia or tiny blood vessels) on the skin
Potential fertility reduction in both males and females
Abnormally heavy menstrual bleeding
Persistent headaches possibly related to vascular changes
Nausea and vomiting associated with bleeding episodes
Potential allergic or hypersensitivity reactions related to protein therapeutics
Injection site reactions including pain, swelling, or redness

Precautions

Regular hematological monitoring of hemoglobin and platelet levels before and during treatment
Avoid use in patients with active serious bleeding or unstable low platelet counts
Assess risks of thromboembolic events in patients with elevated red blood cell mass
Use effective contraception in females of reproductive potential during treatment and for at least 4 months after final dose
Do not breastfeed during treatment and for 4 months post-therapy due to unknown excretion in milk
Caution in patients with bleeding disorders or on concurrent anticoagulants or antithrombotics
Evaluate for potential drug interactions, especially with prostacyclins and blood thinners
Training patients or caregivers thoroughly for correct subcutaneous injection technique
Delay or adjust dosing based on blood test results and clinical status
Monitor for signs of bleeding such as unusual bruising, blood in urine or stool, or persistent headaches
Advise patients to report any unexpected bleeding or bruising immediately
Use caution in patients with compromised fertility or desiring future fertility
Not established as safe or effective in children under 18 years of age
Store medication properly refrigerated and protect from light to maintain stability
Instruct patients on proper handling and disposal of injection materials

Warnings

Risk of erythrocytosis leading to heightened thromboembolic events such as stroke
Potential for severe thrombocytopenia increasing bleeding complications
Serious bleeding risk heightened when co-administered with prostacyclins or anticoagulants
Potential fetal harm; contraindicated in pregnancy without effective contraception
Impaired fertility risks in both male and female patients
Delayed treatment or dosage changes necessary if blood parameters are unstable
Not studied in pediatric populations; safety unknown in children under 18
Avoid administration during active severe bleeding episodes
Possible hypersensitivity or allergic reactions due to biologic protein nature
Risk of medication misuse if patients self-administer without proper training
Reactions at injection site may cause local discomfort or inflammation
Interactions with other medications may alter efficacy or increase adverse events
Risk of increased blood viscosity-related complications needing clinical vigilance
Patients should be educated about recognizing and promptly reporting side effects
Healthcare providers should perform ongoing assessment of benefit versus risk

Contraindication

Active serious bleeding or hemorrhagic conditions
Unstable or severely low platelet counts (thrombocytopenia)
Pregnancy due to potential teratogenic effects and fetal harm
Known hypersensitivity or allergy to sotatercept or any formulation components
Inability to comply with regular hematological monitoring and follow-up
Concurrent severe uncontrolled bleeding disorders
Use in pediatric patients under 18 years until safety established
Patients unwilling or unable to perform, or receive assistance for, subcutaneous injections
Patients with recent history of major thromboembolic events without stabilization
Presence of any contraindication to activin receptor ligand blocking agents
Concurrent use with medications that have contraindicated interactions unless closely monitored
Known malignancy where modulation of TGF-β pathways may pose risk
Severe hypersensitivity reactions to biologic agents
Lack of effective contraception in reproductive potential females
Hypersensitivity to inactive ingredients such as polysorbate 80 or sucrose

Drug Interactions

Increased risk of bleeding when combined with prostacyclins (e.g., iloprost)
Enhanced bleeding risk with concurrent use of anticoagulants such as dabigatran or warfarin
Potential additive effect with antiplatelet agents like clopidogrel increasing hemorrhage risk
Possible interaction with other pulmonary arterial hypertension treatments affecting hematological parameters
No significant cytochrome P450 metabolism interactions expected due to protein nature
Potential pharmacodynamic interactions with drugs impacting coagulation cascades
Caution advised when used with other agents causing thrombocytopenia or bone marrow suppression
Interactions with immunomodulatory agents may alter immune response or efficacy
Concurrent use with hormonal contraceptives requires assessment due to fertility impact
Careful monitoring required when combined with systemic corticosteroids or immunosuppressants
Limited data on interactions with herbal supplements; caution recommended
Avoid use with medications known to cause erythrocytosis or hyperviscosity syndrome
Potential interaction with drugs affecting TGF-β signaling pathways under investigation
Managing polypharmacy in PAH patients requires close coordination to monitor for interactions
Adjust therapy promptly if bleeding signs or hematologic abnormalities develop due to drug interactions

Preparations Of The Drug

Winrevair is supplied as a lyophilized powder in single-dose vials
Available strengths include 45 mg and 60 mg sotatercept-csrk per vial
Requires reconstitution with sterile water for injection prior to administration
The mixed solution must be used within 4 hours and should be stored refrigerated before use
Comes as a kit with mixing instructions and necessary components for subcutaneous injection
Inactive ingredients include citric acid monohydrate, polysorbate 80, sodium citrate, and sucrose
The manufacturer is Merck Sharp & Dohme LLC
Stored in original carton to protect from light at 2°C to 8°C (36°F to 46°F); do not freeze
Once removed from refrigeration can be kept at room temperature (up to 25°C/77°F) for up to 24 hours
Supplied for adult use with detailed prescribing information and patient education materials
Packaging includes instructions for proper disposal of needles and injection devices
Formulated as a sterile biologic product for subcutaneous administration only
Biosimilar and interchangeable products currently not available; Winrevair is the reference product
Storage and handling instructions emphasize maintaining stability and preventing contamination
Patient or caregiver training materials are provided to ensure safe and effective injection technique